Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EBIT (2016 - 2025)

Historic EBIT for iBio (IBIO) over the last 17 years, with Q4 2025 value amounting to -$9.4 million.

  • iBio's EBIT fell 11373.61% to -$9.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$25.5 million, marking a year-over-year decrease of 6370.82%. This contributed to the annual value of -$18.6 million for FY2025, which is 1183.12% down from last year.
  • According to the latest figures from Q4 2025, iBio's EBIT is -$9.4 million, which was down 11373.61% from -$6.0 million recorded in Q3 2025.
  • In the past 5 years, iBio's EBIT registered a high of -$3.4 million during Q2 2024, and its lowest value of -$10.6 million during Q4 2022.
  • In the last 5 years, iBio's EBIT had a median value of -$5.6 million in 2021 and averaged -$6.3 million.
  • As far as peak fluctuations go, iBio's EBIT tumbled by 22226.02% in 2021, and later soared by 5747.66% in 2023.
  • Quarter analysis of 5 years shows iBio's EBIT stood at -$7.2 million in 2021, then crashed by 46.22% to -$10.6 million in 2022, then surged by 57.48% to -$4.5 million in 2023, then grew by 1.71% to -$4.4 million in 2024, then tumbled by 113.74% to -$9.4 million in 2025.
  • Its last three reported values are -$9.4 million in Q4 2025, -$6.0 million for Q3 2025, and -$5.2 million during Q2 2025.